Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 25, 2022
Discovery & Translation

Expanding the CAR T cell toolbox

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 
BioCentury | Apr 29, 2022
Discovery & Translation

Cleavage resistant, regulatable CARs; plus Repertoire, Merus and more

BioCentury’s roundup of translational news
BioCentury | Sep 25, 2017
Company News

Gilead's Sovaldi gets Chinese approval

BioCentury | Aug 3, 2017
Company News

FDA approves AbbVie’s Mavyret for HCV

BioCentury | May 4, 2017
Clinical News

China approves Daklinza/Sunvepra combo for HCV

BioCentury | Apr 28, 2017
Company News

China FDA approves Daklinza combos for HCV

BioCentury | Feb 29, 2016
Clinical News

Daklinza daclatasvir: Phase III data

BioCentury | Feb 29, 2016
Clinical News

Sunvepra asunaprevir: Phase III data

BioCentury | Feb 23, 2016
Clinical News

BMS's oral HCV combo under review in China

Items per page:
1 - 10 of 327
Help Center
Username
Request a Demo
Request Training
Ask a Question